BioSpace News Archive

Business

Korean Pharma’s Phase III COVID Trial Will Compare Candidate to AZ Vaccine

The trial will enroll about 4,000 people worldwide to confirm the drug’s safety and immunogenicity profiles.

August 31, 2021
·
2 min read
·
Vanessa Doctor, RN
Biotech Bay

Startup Runs with Old Novartis Muscle Loss Drug to Fight Obesity

Newly launched Versanis Bio is aiming to turn a Novartis drug that was once developed to help with muscle loss and weakness into an anti-obesity treatment.

August 31, 2021
·
2 min read
·
Alex Keown
Drug Development

Mixed Bag in Phase II Alzheimer’s Trial

AC Immune and Genentech announced that their Phase II Lauriet trial of semorinemab in mild-to-moderate Alzheimer’s disease hit one of its co-primary endpoints.

August 31, 2021
·
3 min read
·
Mark Terry
Business

Outgoing Moderna CMO Lands Seat on Teva Pharmaceuticals Board of Directors

Teva announced the appointment in a filing with the U.S. Securities and Exchange Commission. Zaks will serve on the board’s Science and Technology Committee.

August 31, 2021
·
2 min read
·
Alex Keown
Business

Departure of Founder and CEO Heightens Uncertainty for Galapagos

As CEO, Stolpe has presided over some highs with the launch of JAK1 inhibitor Jyseleca (filgotinib) in Europe, as well as the devaluation of the company’s share price by 70%.

August 31, 2021
·
4 min read
·
BioSpace Editorial Staff
Pharm Country

Study: COVID-19 Deaths Likely Due to Extremely High Viral Load

A new study on COVID-19 behavior has found that patients affected by the virus might have died due to a buildup of coronavirus directly in the lungs and not because of a secondary infection.

August 31, 2021
·
2 min read
·
Vanessa Doctor, RN
Drug Development

J&J’s HIV Vaccine Fails to Protect High-Risk African Women in Trial

Johnson & Johnson announced failed Imbokodo Phase IIb trial in HIV. The study evaluated the company’s investigational HIV vaccine regimen in young women in sub-Saharan Africa.

August 31, 2021
·
3 min read
·
Mark Terry
Drug Development

Cancer Patients Want Warp Speed Given to Oncology Research Next

While the speed of science is both lauded and mistrusted by near-equal parts of the population, the over 22 million Americans with cancer are now saying, “Wait, what about us?”

August 31, 2021
·
3 min read
·
Kate Goodwin
Business

Two of FDA’s Top Vaccine Experts Leaving the Agency

Marion Gruber, director of the agency’s Office of Vaccines Research & Review is leaving at the end of October. Phil Krause, OVRR’s deputy director, is exiting in November.

August 31, 2021
·
2 min read
·
Mark Terry
Deals

Money on the Move: August 25 – 31

The hot days of summer are nearing a close, but these life science companies aren’t cooling off their fundraising efforts. Here’s a brief overview of who’s heating up their coffers this week.

August 31, 2021
·
4 min read
·
Kate Goodwin